- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZ 12012199 | AZ-12012199 | AZ12012199 | AZD 6703 | AZD-6703
Compound class: Synthetic organic
Comment: AZD6703 is a potent, selective and reversible orally bioavailable inhibitor of p38 mitogen-activated protein kinase 14 (MAPK14).
This compound was in the AstraZeneca/MRC repurposing list from 2011.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Brown DS, Cumming JG, Bethel P, Finlayson J, Gerhardt S, Nash I, Pauptit RA, Pike KG, Reid A, Snelson W et al.. (2012)
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Bioorg Med Chem Lett, 22 (12): 3879-83. [PMID:22608965]
2. Clark JE, Sarafraz N, Marber MS. (2007)
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.
Pharmacol Ther, 116 (2): 192-206. [PMID:17765316]
3. Saklatvala J. (2004)
The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.
Curr Opin Pharmacol, 4 (4): 372-7. [PMID:15251131]
4. Schieven GL. (2005)
The biology of p38 kinase: a central role in inflammation.
Curr Top Med Chem, 5 (10): 921-8. [PMID:16178737]